Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
$0.33
-2.9%
$0.37
$0.80
$1.82
$2.99M2.034,760 shs15,017 shs
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
$2.06
+2.0%
$13.23
$4.50
$27.32
$2.96M2.0778,851 shs81,544 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$0.16
$0.15
$0.12
$1.52
$2.50M1.281.60 million shs108,630 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
0.00%-12.66%-5.36%-13.49%-38.61%
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
0.00%+25.48%-7.08%+8.24%-12.05%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
+0.25%+2.43%+1.52%-2.31%-83.75%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.785 of 5 stars
3.53.00.00.01.10.01.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
3.00
Buy$3.251,931.25% Upside

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/A($0.07) per shareN/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/AN/AN/AN/A$13.13 per shareN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$13.27M0.19N/AN/A$1.72 per share0.09

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
-$1.11M-$0.40N/AN/AN/AN/A-288.85%N/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
-$16.01M-$21.58N/AN/AN/AN/A-133.49%-30.52%N/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$5.15M-$0.97N/AN/AN/A-41.24%-58.93%-26.92%6/19/2024 (Estimated)

Latest NVUS, ICOTF, and SNOA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/8/202412/31/2023
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.21-$0.06+$0.15-$0.04N/A$3.14 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/AN/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A
0.72
0.72
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/A
18.78
18.78
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
4.07
3.11

Ownership

Institutional Ownership

CompanyInstitutional Ownership
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
N/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%

Insider Ownership

CompanyInsider Ownership
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
2.20%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
9.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A9.05 millionN/ANot Optionable
Novus Therapeutics, Inc. stock logo
NVUS
Novus Therapeutics
71.44 millionN/ANot Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
915.61 million14.17 millionNot Optionable

NVUS, ICOTF, and SNOA Headlines

SourceHeadline
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United StatesSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States
finanznachrichten.de - April 9 at 10:39 AM
Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United StatesSonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States
accesswire.com - April 9 at 7:30 AM
Sonoma Pharmaceuticals Reports Recent Publication…Sonoma Pharmaceuticals Reports Recent Publication…
pharmiweb.com - April 4 at 10:28 AM
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract InfectionsSonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections
accesswire.com - April 4 at 7:30 AM
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor ConferencesSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
finanznachrichten.de - March 28 at 9:52 PM
Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor ConferencesSonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences
accesswire.com - March 28 at 4:01 PM
Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other TopicalsSonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals
accesswire.com - March 27 at 7:30 AM
Sonoma Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagSonoma Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
finance.yahoo.com - February 10 at 2:56 PM
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial ResultsSonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results
finance.yahoo.com - February 8 at 4:32 PM
Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily UseSonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily Use
finance.yahoo.com - January 23 at 9:51 AM
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial ResultsSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results
finanznachrichten.de - November 13 at 5:52 PM
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial ResultsSonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results
finance.yahoo.com - November 13 at 5:52 PM
Sonoma Pharmaceuticals Inc SNOASonoma Pharmaceuticals Inc SNOA
morningstar.com - November 11 at 10:31 PM
Sonoma Pharmaceuticals Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation at the Symposium on Advanced Wound Care Fall ConferenceSonoma Pharmaceuticals Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation at the Symposium on Advanced Wound Care Fall Conference
finance.yahoo.com - November 3 at 8:49 AM
US Stocks Mixed; Bristol Myers Posts Upbeat EarningsUS Stocks Mixed; Bristol Myers Posts Upbeat Earnings
benzinga.com - October 26 at 6:54 PM
Crude Oil Down 2.5%; Mastercard Posts Upbeat EarningsCrude Oil Down 2.5%; Mastercard Posts Upbeat Earnings
markets.businessinsider.com - October 26 at 6:54 PM
Dow Dips Over 100 Points; US GDP Growth Tops ExpectationsDow Dips Over 100 Points; US GDP Growth Tops Expectations
benzinga.com - October 26 at 1:54 PM
Sonoma Pharmaceuticals, Inc. Announces Pricing of $1.7 Million Public Offering of Common StockSonoma Pharmaceuticals, Inc. Announces Pricing of $1.7 Million Public Offering of Common Stock
finance.yahoo.com - October 26 at 1:54 PM
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.62%U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.62%
msn.com - October 24 at 10:20 PM
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.62%U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.62%
msn.com - October 24 at 5:19 PM
macOS Sonoma now available: Heres whats newmacOS Sonoma now available: Here's what's new
pocketnow.com - September 29 at 3:54 PM
macOS SonomamacOS Sonoma
macrumors.com - September 28 at 12:39 PM
Apple macOS Sonoma system requirements – can macOS 14 run on your Mac?Apple macOS Sonoma system requirements – can macOS 14 run on your Mac?
stuff.tv - September 14 at 7:13 AM
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn AdvancedNational Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
finance.yahoo.com - August 15 at 10:23 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

iCo Therapeutics logo

iCo Therapeutics

OTCMKTS:ICOTF
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.
Novus Therapeutics logo

Novus Therapeutics

NASDAQ:NVUS
Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.
Sonoma Pharmaceuticals logo

Sonoma Pharmaceuticals

NASDAQ:SNOA
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.